Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688266'
s EV-to-FCF Range Over the Past 10 Years
Min: -766.08 Med: -32.68 Max: 58.28
Current: 54.69
During the past 10 years, the highest EV-to-FCF of Suzhou Zelgen Biopharmaceuticals Co was 58.28. The lowest was -766.08. And the median was -32.68.
SHSE:688266's EV-to-FCF is ranked worse than 80.42% of 337
companies
in the Biotechnology industry
Industry Median: 15.15
vs SHSE:688266: 54.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Suzhou Zelgen Biopharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Suzhou Zelgen Biopharmaceuticals Co's share price for today is ¥140.00.
Suzhou Zelgen Biopharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Suzhou Zelgen Biopharmaceuticals Co EV-to-FCF Related Terms
Suzhou Zelgen Biopharmaceuticals Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co EV-to-FCF Chart
SHSE:688266 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Zelgen Biopharmaceuticals Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's EV-to-FCF falls into.
Suzhou Zelgen Biopharmaceuticals Co's current Enterprise Value is ¥35,679 Mil.
Suzhou Zelgen Biopharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥633 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a EV-to-FCF of 56.33 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #271 out of 337 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Suzhou Zelgen Biopharmaceuticals Co's EV-to-FCF too high?
Suzhou Zelgen Biopharmaceuticals Co's current EV-to-FCF is 56.33. The Biotechnology industry median EV-to-FCF is 15.15. Suzhou Zelgen Biopharmaceuticals Co's value of 56.33 is 271.8% above this industry median. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #271 out of 337 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #271 out of 337 companies for EV-to-FCF. This places Suzhou Zelgen Biopharmaceuticals Co in the lower half of its industry. The industry median EV-to-FCF is 15.15. Suzhou Zelgen Biopharmaceuticals Co's value of 56.33 is 271.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.15, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Zelgen Biopharmaceuticals Co's current EV-to-FCF of 56.33 is 271.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Zelgen Biopharmaceuticals Co's current EV-to-FCF is 56.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥216.30, compared to a current price of ¥140.00 — trading 35.3% below its estimated fair value. The current EV-to-FCF is 56.33 and 271.8% above the Biotechnology industry median of 15.15. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current EV-to-FCF is 56.33 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥140.00 is trading 35.3% below its estimated GF Value™ of ¥216.30.
GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for SHSE:688266:
EV-to-FCF: 56.33
GF Value™: ¥216.30 vs. price of ¥140.00 (35.3% below fair value)
Industry Position: 271.8% above the Biotechnology median (#271 of 337)
No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Zelgen Biopharmaceuticals Co Business Description
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
67GF Score
Get the complete analysis for SHSE:688266
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688266 has been successfully added to your 
